Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | ubiquitin specific peptidase 1 | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | IMP dehydrogenas | 0.0162 | 0.7578 | 1 |
Loa Loa (eye worm) | IMP dehydrogenase 1 | 0.0162 | 0.7578 | 1 |
Wolbachia endosymbiont of Brugia malayi | IMP dehydrogenase | 0.0162 | 0.7578 | 0.5 |
Mycobacterium ulcerans | inosine 5-monophosphate dehydrogenase | 0.0153 | 0.7024 | 0.8869 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Trypanosoma cruzi | inosine-5'-monophosphate dehydrogenase, putative | 0.0162 | 0.7578 | 1 |
Leishmania major | guanosine monophosphate reductase | 0.0162 | 0.7578 | 1 |
Trypanosoma brucei | inosine-5'-monophosphate dehydrogenase | 0.0162 | 0.7578 | 1 |
Onchocerca volvulus | Putative GMP reductase | 0.0068 | 0.2128 | 0.5 |
Trypanosoma cruzi | GMP reductase | 0.0162 | 0.7578 | 1 |
Trypanosoma cruzi | inosine-5'-monophosphate dehydrogenase, putative | 0.0162 | 0.7578 | 1 |
Leishmania major | inosine-5-monophosphate dehydrogenase | 0.0162 | 0.7578 | 1 |
Brugia malayi | inosine-5'-monophosphate dehydrogenase family protein | 0.0162 | 0.7578 | 1 |
Trypanosoma cruzi | GMP reductase | 0.0162 | 0.7578 | 1 |
Mycobacterium leprae | Probable inosine-5'-monophosphate dehydrogenase GuaB3 (IMP dehydrogenase 2) (inosinic acid dehydrogenase) (inosinate dehydrogena | 0.0085 | 0.3149 | 0.0954 |
Trypanosoma brucei | GMP reductase | 0.0162 | 0.7578 | 1 |
Brugia malayi | GMP reductase | 0.0068 | 0.2128 | 0.2808 |
Loa Loa (eye worm) | GMP reductase | 0.0068 | 0.2128 | 0.2808 |
Mycobacterium ulcerans | inosine 5'-monophosphate dehydrogenase | 0.0162 | 0.7578 | 1 |
Trypanosoma cruzi | inosine-5'-monophosphate dehydrogenase, putative | 0.0162 | 0.7578 | 1 |
Mycobacterium leprae | Probable inosine-5'-monophosphate dehydrogenase GuaB2 (IMP dehydrogenase) (IMPDH) (IMPD) | 0.0162 | 0.7578 | 1 |
Plasmodium falciparum | inosine-5'-monophosphate dehydrogenase | 0.0153 | 0.7024 | 1 |
Plasmodium vivax | inosine-5'-monophosphate dehydrogenase, putative | 0.0153 | 0.7024 | 1 |
Brugia malayi | inosine-5'-monophosphate dehydrogenase | 0.0068 | 0.2128 | 0.2808 |
Echinococcus multilocularis | geminin | 0.0205 | 1 | 1 |
Brugia malayi | inosine-5'-monophosphate dehydrogenase | 0.0068 | 0.2128 | 0.2808 |
Mycobacterium tuberculosis | Probable inosine-5'-monophosphate dehydrogenase GuaB2 (imp dehydrogenase) (inosinic acid dehydrogenase) (inosinate dehydrogenase | 0.0162 | 0.7578 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7079 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 5.0119 uM | PubChem BioAssay. Inhibitors of USP1/UAF1: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 16.3601 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.